Soleus Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Soleus Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.61M	Buy	+950,000	New	+$3.79M	0.16%	76

Other funds holding ZNTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Soleus Capital Management's ZNTL Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 950,000 shares worth $4.61M. The stake represents 0.16% of the portfolio and ranks #76 among its holdings.

38 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Soleus Capital Management held 950,000 shares of Zentalis Pharmaceuticals worth $4.61M as of Q2 2026.
Zentalis Pharmaceuticals was a new Soleus Capital Management position in Q2 2026.
Zentalis Pharmaceuticals made up 0.16% of Soleus Capital Management's portfolio in Q2 2026, its #76 holding.
38 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.